Investor/trader focused primarily in the biopharma sector. Tweets are not investment advice and are not recommendations of any kind.
Toronto
Joined February 2010
- Tweets61.8K
- Following93
- Followers72.4K
- Likes625
Pinned Tweet
Big Pharma M&A set for mega year as patent expiries drive deal urgency. $XBI $IBB
If the current pace holds, 2026 biopharma M&A could top $250 billion, making it the #2 year on record after 2019’s $328 billion. #biotech
ca.finance.yahoo.com/news/bi…
$ZYME Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at #ESMO26
cORR of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer
ir.zymeworks.com/news-releas…
$RVMD Presents OS Data for RASONQUE Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at #ESMO26 $TNGX
The subgroup analyses showed RASONQUE consistently provided an OS benefit across key subgroups, including patients with no identified tumor RAS mutation
globenewswire.com/news-relea…
$ZLAB Zocilurtatug Pelitecan Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
businesswire.com/news/home/2…
$ZLAB $250M PIPE at $22.04/ADS
The financing is led by TCGX and includes participation from ADAR1 Capital, Balyasny Asset Management, Cormorant, Frazier Life Sciences, RA Capital, RTW Investments, Sirenia Capital, Wellington Management and Woodline Partners
$TNGX Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer. $RVMD
82% ORR, median PFS not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib
ir.tangotx.com/news-releases…
$ZYME Enters into a Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3. $RHHBY
Zymeworks to receive $55M upfront and a $40M payment upon initiation of the Phase 1b trial
ir.zymeworks.com/news-releas…
$ZLAB $250M PIPE at $22.04/ADS
The financing is led by TCGX and includes participation from ADAR1 Capital, Balyasny Asset Management, Cormorant, Frazier Life Sciences, RA Capital, RTW Investments, Sirenia Capital, Wellington Management and Woodline Partners
$MRNA drop reflects high bar, not bad data - Mizuho’s Jared Holz
cnbc.com/video/2026/10/22/mi…
$DMAC Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial.
Interim Analysis Results Expected in Q1'27
$CRBP to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week 2026
ir.corbuspharma.com/news-eve…
$CGTX Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
globenewswire.com/de/news-re…
$MRNA PT raised to $90 at TD Cowen
The analyst increased the peak INT profit estimate to Moderna to apprx $3.4B in 2035, from prior estimate of $830M
$IBRX Announces Database Lock for Registrational Trial of ANKTIVA Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer.
- Topline data expected in November
- sBLA submission on track for Q4
businesswire.com/news/home/2…
Yakira Capital Calls on $RNA to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Questions decision to raise $50M after shares fell apprx 44% at a valuation near 50% of net cash
prnewswire.com/news-releases…
$PALI Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at #UEG26
Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days
ir.palisadebio.com/palisade-…